A novel extracorporeal liver assist device, called the University College London–Liver Dialysis Device, which removes dysfunctional albumin has been studied in a pig model of paracetamol-induced acute liver failure. If initiated 2 h after irreversible liver failure, device treatment resulted in a 67% reduced risk of death compared with a control device. A 54% reduction in overall severity of endotoxaemia and delays in the development of vasoplegia were also observed with the novel device.